30 related articles for article (PubMed ID: 12646097)
1. S-100B concentrations predict disease-free survival in stage III melanoma patients.
Kruijff S; Bastiaannet E; Kobold AC; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2009 Dec; 16(12):3455-62. PubMed ID: 19636631
[TBL] [Abstract][Full Text] [Related]
2. Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas.
Wagner V; Rudi J; Näher H; Stremmel W
Med Oncol; 2000 Feb; 17(1):35-8. PubMed ID: 10713658
[TBL] [Abstract][Full Text] [Related]
3. Iontophoretic beta-adrenergic stimulation of human sweat glands: possible assay for cystic fibrosis transmembrane conductance regulator activity in vivo.
Shamsuddin AK; Reddy MM; Quinton PM
Exp Physiol; 2008 Aug; 93(8):969-81. PubMed ID: 18441335
[TBL] [Abstract][Full Text] [Related]
4. Classic Rett syndrome in a boy with R133C mutation of MECP2.
Masuyama T; Matsuo M; Jing JJ; Tabara Y; Kitsuki K; Yamagata H; Kan Y; Miki T; Ishii K; Kondo I
Brain Dev; 2005 Sep; 27(6):439-42. PubMed ID: 16122633
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.
Tarhini AA; Stuckert J; Lee S; Sander C; Kirkwood JM
J Clin Oncol; 2009 Jan; 27(1):38-44. PubMed ID: 19047287
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
Kumar R; Alavi A
Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
Mruck S; Baum RP; Rinne D; Hör G
Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
[TBL] [Abstract][Full Text] [Related]
8. S100 protein serum levels in cutaneous malignant melanoma.
Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
[TBL] [Abstract][Full Text] [Related]
9. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data.
Reinhardt MJ; Kensy J; Frohmann JP; Willkomm P; Reinhold U; Grünwald F; Biersack HJ; Bender H
Nuklearmedizin; 2002 Jun; 41(3):143-7. PubMed ID: 12109034
[TBL] [Abstract][Full Text] [Related]
10. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
[TBL] [Abstract][Full Text] [Related]
12. [S100 protein as tumoral marker in melanoma patients. Comparative study with sentinel node biopsy and whole body FDG-PET].
Ortiz B; Vázquez C; Martínez C; Giménez J; Sanmartín O; de los Dolores V; Ortega F; Maíquez J; Fliquete MV
Rev Esp Med Nucl; 2003; 22(2):87-96. PubMed ID: 12646097
[TBL] [Abstract][Full Text] [Related]
13. Fluorodeoxyglucose-PET in the management of malignant melanoma.
Kumar R; Mavi A; Bural G; Alavi A
Radiol Clin North Am; 2005 Jan; 43(1):23-33. PubMed ID: 15693645
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
